Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 509-518

  Ruhlmann, Christina H ^a   Christensen, Thomas Broe ^b   Dohn, Line Hammer ^c   Paludan, Merete ^d   Rønnengart, Eva ^b   Halekoh, Ulrich ^e   Hilpert, Felix ^f   Feyer, Petra ^g   Kristensen, Gunnar ^h   Hansen, Olfred ^a,e   Keefe, Dorothy ⁱ   Herrstedt, Jørn ^a,e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c University of Copenhagen   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; FOSAPREPITANT; PALONOSETRON; PLACEBO; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; MORPHOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FEVER; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; UTERINE CERVIX CANCER; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; ISOQUINOLINES; MIDDLE AGED; MORPHOLINES; NAUSEA; QUINUCLIDINES; UTERINE CERVICAL NEOPLASMS; VOMITING;

EID: 84959451679     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00615-4     Document Type: Article

References (36)

1. 1 Enblom, A, Bergius Axelsson, B, Steineck, G, et al. One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17 (2009), 23–32.
2. 2 Italian Group for Antiemetic Research. Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy. Int J Radiat Oncol Biol Phys 44 (1999), 619–625.
3. 3 Maranzano, E, De Angelis, V, Pergolizzi, S, et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94 (2010), 36–41.
4. 4 Gralla, RJ, Bosnjak, SM, Hontsa, A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25 (2014), 1333–1339.
5. 5 Herrstedt, J, Muss, HB, Warr, DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104 (2005), 1548–1555.
6. 6 Hesketh, PJ, Grunberg, SM, Gralla, RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21 (2003), 4112–4119.
7. 7 Hesketh, PJ, Rossi, G, Rizzi, G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25 (2014), 1340–1346.
8. 8 Poli-Bigelli, S, Rodrigues-Pereira, J, Carides, AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97 (2003), 3090–3098.
9. 9 Rapoport, B, Chasen, M, Gridelli, C, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomised phase 3 trials. Lancet Oncol 16 (2015), 1079–1089.
10. 10 Schmoll, HJ, Aapro, MS, Poli-Bigelli, S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17 (2006), 1000–1006.
11. 11 Schwartzberg, L, Modiano, M, Rapoport, B, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomised phase 3 trial. Lancet Oncol 16 (2015), 1071–1078.
12. 12 Warr, DG, Hesketh, PJ, Gralla, RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23 (2005), 2822–2830.
13. 13 Aapro, M, Rugo, H, Rossi, G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25 (2014), 1328–1333.
14. 14 Emami, H, Hematti, S, Saeidian, SM, et al. The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting. J Res Med Sci 20 (2015), 329–333.
15. 15 Ruhlmann, CH, Belli, C, Dahl, T, et al. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study. Support Care Cancer 21 (2013), 3425–3431.
16. 16 Jahn, F, Riesner, A, Jahn, P, et al. Addition of the neurokinin-1-receptor antagonist (RA) aprepitant to a 5-hydroxytryptamine-RA and dexamethasone in the prophylaxis of nausea and vomiting due to radiation therapy with concomitant cisplatin. Int J Radiat Oncol Biol Phys 92 (2015), 1101–1107.
17. 17 Grunberg, S, Chua, D, Maru, A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29 (2011), 1495–1501.
18. 18 Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
19. 19 Scheike, TH, Zhang, MJ, Analyzing competing risk data using the R timereg package. J Stat Software 38 (2011), 1–15.
20. 20 Gray, RJ, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
21. 21 Lundberg, JD, Crawford, BS, Phillips, G, et al. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer 22 (2014), 1461–1466.
22. 22 Sato, Y, Kondo, M, Inagaki, A, et al. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer 5 (2014), 390–397.
23. 23 de Wit, R, Herrstedt, J, Rapoport, B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21 (2003), 4105–4111.
24. 24 de Wit, R, Herrstedt, J, Rapoport, B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40 (2004), 403–410.
25. 25 Herrstedt, J, Sigsgaard, TC, Nielsen, HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15 (2007), 417–426.
26. 26 Hesketh, PJ, Aapro, M, Street, JC, et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18 (2010), 1171–1177.
27. 27 Roila, F, Herrstedt, J, Aapro, M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:suppl 5 (2010), v232–v243.
28. 28 Marbury, TC, Ngo, PL, Shadle, CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 51 (2011), 1712–1720.
29. 29 Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16 (1998), 2937–2942.
30. 30 Saito, M, Aogi, K, Sekine, I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10 (2009), 115–124.
31. 31 Navari, RM, Nagy, CK, Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. Proc Am Soc Clin Oncol, 33(suppl 5s), 2015 abstract 9502.
32. 32 de Boer-Dennert, M, de Wit, R, Schmitz, PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76 (1997), 1055–1061.
33. 33 Sun, CC, Bodurka, DC, Weaver, CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13 (2005), 219–227.
34. 34 Feyer, PC, Maranzano, E, Molassiotis, A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19:suppl 1 (2011), S5–14.
35. 35 Albany, C, Brames, MJ, Fausel, C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study. J Clin Oncol 30 (2012), 3998–4003.
36. 36 Einhorn, LH, Brames, MJ, Dreicer, R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15 (2007), 1293–1300.